Immunoprecise Antibodies Ltd
XTSX:IPA
Immunoprecise Antibodies Ltd
XTSX:IPA
Price:
6.5 CAD
0.78%
Market Closed
Updated:
May 6, 2024
Immunoprecise Antibodies Ltd
Operating Income
|
Immunoprecise Antibodies Ltd
Operating Income Peer Comparison
Comparables:
ABCL
ARCH
RP
IOT
Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Immunoprecise Antibodies Ltd
XTSX:IPA
|
Operating Income
-CA$6.9m
|
CAGR 3-Years
-13%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abcellera Biologics Inc
NASDAQ:ABCL
|
Operating Income
-$237.2m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-212%
|
CAGR 10-Years
N/A
|
|
|
Arch Biopartners Inc
XTSX:ARCH
|
Operating Income
-CA$5.1m
|
CAGR 3-Years
15%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-38%
|
|
|
Replicel Life Sciences Inc
XTSX:RP
|
Operating Income
-CA$1.4m
|
CAGR 3-Years
12%
|
CAGR 5-Years
11%
|
CAGR 10-Years
N/A
|
|
|
Innovotech Inc
XTSX:IOT
|
Operating Income
-CA$219.6k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-9%
|
CAGR 10-Years
13%
|
See Also
What is Immunoprecise Antibodies Ltd's Operating Income?
Operating Income
-6.9m
CAD
-6.9m
CAD
Based on the financial report for Apr 30, 2021, Immunoprecise Antibodies Ltd's Operating Income amounts to -6.9m CAD.
What is Immunoprecise Antibodies Ltd's Operating Income growth rate?
Operating Income CAGR 3Y
-13%
-13%
Over the last year, the Operating Income growth was -69%. The average annual Operating Income growth rates for Immunoprecise Antibodies Ltd have been -13% over the past three years .
You don't have any saved screeners yet
